{"id":8090,"date":"2023-08-04T10:26:14","date_gmt":"2023-08-04T10:26:14","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=8090"},"modified":"2023-08-04T10:28:47","modified_gmt":"2023-08-04T10:28:47","slug":"pd-1-cd279-pd-l1-cd274-pathway","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/pd-1-cd279-pd-l1-cd274-pathway\/","title":{"rendered":"PD-1 [CD279]\/PD-L1 [CD274] Pathway"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

PD-1 (Programmed cell death protein 1; CD279) is a type I transmembrane protein belonging to the CD28\/CTLA-4 family of immune receptors. PD-L1 (CD274; B7-H1) and PD-L2 (B7-DC; CD273) are immuno-coinhibitory ligands of the B7 family binding to PD-1. The PD-1\/PD-L1 or PD-L2 signalling pathway is a negative regulatory mechanism that inhibits T cell proliferation and cytokine production. Blockade of the PD-1\/PD-L1 interaction enhances antitumor immunity. The PD-1 pathway plays a major role in the inhibition of self-reactive T cells and protection against autoimmune diseases. PD-1 and PD-L1 also exist as soluble forms. Elevated levels of soluble PD-1 (sPD-1) are shown in rheumatoid arthritis, skin sclerosis and autoimmune hepatitis. Levels of sPD-L1 are increased in the plasma of cancer patients as well as in the cerebrospinal fluid of gliomas. sPD-L1 is a biomarker of poor survival in patients with B cell lymphoma, renal cell carcinoma, metastatic melanoma or lung cancer and is associated with advanced tumour stages.<\/p>\n\n\n\n

LIT:<\/strong>\u00a0\u00a0PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues: J. Hamanishi, et al.; Int. J. Clin. Oncol.\u00a021,<\/strong>\u00a0462 (2016) \u2022 PD-1\/PD-L1 immune checkpoint: Potential target for cancer therapy: F.K. Dermani, et al.; J. Cell Physiol.\u00a0234,<\/strong>\u00a01313 (2019)<\/p>\n\n\n\n

PD-1 (human) ELISA Kit\u00a0 –\u00a0 Biomarker for Immuno-Oncology & Autoimmune Diseases<\/strong><\/p>\n\n\n\n

The PD-1 (human) ELISA Kit (Prod. No. AG-45B-0015<\/a>) is a sandwich ELISA for the specific quantitative determination of human soluble PD-1 in serum, plasma and cell culture supernatants. This ELISA Kit shows a very high specificity and sensitivity (1.6pg\/ml).<\/p>\n\n\n\n

PD-L1 (human) ELISA Kit\u00a0 –\u00a0Tumour Biomarker for Poor Survival Prognosis<\/strong><\/p>\n\n\n\n

The PD-L1 (human) ELISA Kit (Prod. No. AG-45B-0016<\/a>) is a sandwich ELISA for the specific quantitative determination of human soluble PD-L1 in serum, plasma and cell culture supernatants. This ELISA Kit shows a very high specificity and sensitivity (0.8pg\/ml).<\/p>\n\n\n\n

PD-L1 (mouse):Fc (mouse) (rec.)\u00a0 –\u00a0Biologically Active Proteins<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

PD-L1 (mouse):Fc (mouse) (rec.) (Prod. No. CHI-MF-110PDL1<\/a>) is a biologically active recombinant fusion protein that inhibits anti-CD3\/CD28 antibody-induced proliferation of mouse T lymphocytes.<\/p>\n\n\n\n

Biological Activity:\u00a0T cells from C57BL\/6 mice were activated with coated anti-CD3\/CD28 and PD-L1-Fc or control antibody (10\u00b5g\/ml). Plots\u00a0illustrate the percentage of dividing cells by using anti-CD44 and the dye Cell Trace Violet (CTV).<\/p>\n\n\n\n

anti-PD-1 (mouse), mAb (blocking) (1H10)<\/strong><\/p>\n\n\n\n

AdipoGen Life Sciences’ anti-PD-1 (mouse), mAb (blocking) (1H10) (Prod. No. AG-20B-0075<\/a>) is a monoclonal antibody that recognises mouse PD-1 and works specifically in Flow Cytometry and Functional Application. The antibody blocks PD-1 binding and induces a rapid activation and proliferation of T cells at a concentration of 0.25\u00b5g\/2×105<\/sup>\u00a0cells. The antibody is available with or without preservatives.<\/p>\n\n\n\n

\"\"<\/a>
Figure:\u00a0<\/strong>PD-1 receptor-induced CD4 T cell activation and proliferation by PD-1 (mouse), mAb (blocking) (1H10) (AG-20B-0075).<\/figcaption><\/figure>\n\n\n\n

Method:\u00a0<\/strong>Magnetic bead affinity purified CD4+ T cells from C57BL\/6 mice are stimulated\u00a0in vitro<\/em>\u00a0with PD-1 (mouse), mAb (blocking) (1H10), anti-CD28 and rat IgG2a isotype (control Ig) (0.25\u00b5g\/2×105<\/sup>\u00a0cells) for 48h. Proliferation is determined by [3H]thymidine incorporation. The presence of anti-CD28 mAb increases 1H10 mAb-mediated proliferation.<\/p>\n\n\n\n

IHC-Competent Antibodies for PD-1 and PD-L1 Staining<\/strong><\/p>\n\n\n\n

AdipoGen Life Sciences’\u00a0anti-PD-1 (human), mAb (AG-IHC001)\u00a0(Prod. No. AG-20B-6020<\/a>) and\u00a0anti-PD-L1 (human), mAb (AG-IHC411)\u00a0(Prod. No. AG-20B-6022<\/a>) are monoclonal antibodies that recognize human PD-1 and PD-L1, respectively, and work specifically in Immunohistochemistry Application. The antibodies are available in catalogue and BULK sizes.<\/p>\n\n\n\n

\"\"<\/a>
Figure:<\/strong>\u00a0IHC Staining of PD-1 in human tonsil tissue using anti-PD-1 (human), mAb (AG-IHC001) (Prod. No. AG-20B-6020)<\/figcaption><\/figure>\n\n\n\n
\"\"<\/a>
Figure:<\/strong>\u00a0IHC Staining of PD-L1 in human lung tissue using anti-PD-L1 (human), mAb (AG-IHC411) (Prod. No. AG-20B-6022)<\/figcaption><\/figure>\n\n\n\n

Biologically Active\u00a0PD-1 and PD-L1 Proteins<\/strong><\/p>\n\n\n\n

See all biologically active\u00a0PD-1 and PD-L1 proteins here<\/a>.<\/p>\n\n\n\n

Validated\u00a0Antibodies for PD-1 and PD-L1 Research<\/strong><\/p>\n\n\n\n

See all validated\u00a0antibodies for PD-1 and PD-L1 research by AdipoGen Life Sciences here<\/a>.<\/p>\n\n\n\n

See all validated antibodies for PD-1 and PD-L1 research by Ancell here<\/a>.<\/p>\n\n\n\n

\n
Back to T Cell Immune Checkpoints for Immuno-Oncology Research<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

Originally posted on\u00a0adipogen.com\/pd-1-pd-l1-pathway<\/a><\/p>\n\n\n\n

Caltag Medsystems <\/a>is the distributor of Adipogen<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

The PD-1\/PD-L1 or PD-L2 signalling pathway is a negative regulatory mechanism that inhibits T cell proliferation and cytokine production.<\/p>\n","protected":false},"author":13,"featured_media":8117,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,1,637],"tags":[279,143,7,8,684,683],"class_list":["post-8090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-general-information","category-t-cells","tag-adipogen","tag-antibody","tag-cancer","tag-elisa","tag-pathway","tag-proteins"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=8090"}],"version-history":[{"count":19,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8090\/revisions"}],"predecessor-version":[{"id":8118,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8090\/revisions\/8118"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/8117"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=8090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=8090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=8090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}